# US 2025/0049850 A1 · Non-viral b cell engineering methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049850 A1
- Document ID: US20250049850A1
- Status: Published application
- Kind: A1
- Application number: 18/720,158
- Filed: 2022-12-15
- Published: 2025-02-13
- Earliest claimed: 2021-12-15
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Branden S. Moriarity; Kanut Laoharawee; Beau R. Webber; Evan Kleinboehl
- Web page: https://patentgrep.com/patent/US20250049850A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61P 35/00: Antineoplastic agents
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 5/0635: {B lymphocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/15: chimeric enhancer/promoter combination
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12Y 302/01076: L-Iduronidase (3.2.1.76)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates, in general, to non-viral methods for generating engineered B cell, and use of such B cells as cell-based therapeutics to treat disease.

## Claims

### Claim 1

A method for genome engineering a B cell or a population of B cells to overexpress a gene of interest comprising introducing into the B cell or B cell population a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm (HA), a polynucleotide encoding a gene of interest, a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule,
wherein the expression cassette is inserted at a locus targeted by the targeting molecule.

### Claim 2

A method for genome engineering a B cell or a population of B cells to overexpress an endogenous gene comprising introducing into the B cell or B cell population a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm(s) (HA), a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule,
wherein the expression cassette is inserted upstream of a target gene to be overexpressed.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the homology arms are between 35 and 1000 nucleotides.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the nuclease dependent cleavage system comprises a CRISPR/Cas system, a Cas-CLOVER system, a zinc-finger nuclease (ZFN) system, a transcription activator like effector nuclease (TALEN) system, or a meganuclease system.

### Claim 5 (depends on 4)

The method of claim 4, wherein the CRISPR/Cas system comprises Cas9, Cas12a, Cas13a or Cas13b.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the nuclease dependent cleavage system is a CRISPR/Cas system and the targeting molecule is a guide RNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method further comprises transfecting the B cell or population of B cells with a Cas protein or polynucleotide encoding a Cas protein and guide RNA molecules that direct integration of the expression cassette to a target locus in the B cell genome.

### Claim 8

The method of any one of the preceding claims, further comprising introducing into the B cell or B cell population a polynucleotide encoding a biomarker molecule useful to enrich for the B cell or a population of B cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the biomarker molecule comprises a fragment of CD34 and a fragment of CD20.

### Claim 10 (depends on 1, 2, 8, 9)

The method of claim 8 or 9, wherein the biomarker polynucleotide is on the same expression cassette as the homology arm(s), splice acceptor site, targeting site for a nuclease dependent cleavage system targeting molecule and promoter of claim 1 or 2.

### Claim 11

The method of any one of the preceding claims, wherein the gene of interest integrates into the B cell genome via homology directed repair (HDR), homology-mediated end joining (HMEJ) or a combination of HDR/HMEJ.

### Claim 12

The method of any one of the preceding claims, wherein the introduction of the plasmid or nanoplasmid is by transfection or electroporation.

### Claim 13

The method of any one of the preceding claims, wherein efficiency of introduction is greater than 15%.

### Claim 14

The method of any one of the preceding claims, wherein the B cell population has a viability of greater than 60% after 3 days.

### Claim 15

The method of any one of the preceding claims, wherein the B cell or population of B cells is a primary B cell, a plasma cell, a mature B cell, a B cell line, naïve B cell, memory B cells, or plasma blast.

### Claim 16

The method of any one of the preceding claims, wherein the plasmid or nanoplasmid comprises the promoter next to or near the gene of interest.

### Claim 17 (depends on 16)

The method of claim 16, wherein the promoter is an MND promoter, a CMV promoter, a CAG promoter, a PGK promoter, a EF1A promoter, a FEEK promoter, or a B cell-specific promoter.

### Claim 18

The method of any one of the preceding claims, wherein the gene of interest is a therapeutic gene or encodes a therapeutic protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutic gene encodes an enzyme, a cancer antigen, a cytokine, a chemokine, a B cell receptor, a cell surface receptor, or an antibody.

### Claim 20

The method of any one of the preceding claims, wherein the gene of interest is a donor polynucleotide that corrects a mutated genotype in a subject.

### Claim 21

The method of any one of the preceding claims, wherein the plasmid or nanoplasmid further comprises a polynucleotide encoding a B cell receptor or fragment thereof.

### Claim 22

A method of making a gene edited B cell or population of B cells, comprising:
i) contacting a B cell or population of B cells with a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm (HA), a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule, and optionally comprising a polynucleotide encoding a gene of interest;
ii) culturing the B cell or population of B cells of i) in a media that promotes expansion of B cells;
iii) isolating the B cell or population of B cells of ii) based on identification of a marker expressed only on a B cell or population of B cells carrying the plasmid or nanoplasmid;
iv) culturing the isolated cells of iii) in a culture medium to expand the isolated cells expressing the gene of interest.

### Claim 23 (depends on 22)

The method of claim 22 further comprising a step of stimulating, proliferating or activating the B cell or population of B cells prior to the contacting step.

### Claim 24 (depends on 23)

The method of claim 23, wherein the step of stimulating, proliferating or activating the B cell or population of B cells comprises contacting the cell(s) with one or more of CpG, LPS, CD40L, Anti-IgM, IL-10, IL-15, IL-2, IL-6, IFNα, APRIL or BAFF.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22-24, wherein the method produces gene edited B cells with an efficiency of greater than 15%.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22-25, wherein the method maintains 60% viability of cells in culture after 3 days.

### Claim 27 (depends on 22)

The method of claim 22, wherein the culturing comprises use of culture media supplemented with CpG, or culturing media without CpG.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A gene edited B cell or population of B cells made by the method of any one of claims 1-27.

### Claim 29

A gene edited B cell comprising
i) a heterologous polynucleotide sequence encoding a gene of interest integrated in the B cell genome at a target location mediated by a nuclease dependent cleavage system, wherein the heterologous polynucleotide sequence is also flanked by portions of a homology arm and expressed via an endogenous promoter; and
ii) a heterologous biomarker molecule.

### Claim 30 (depends on 29)

The gene edited B cell of claim 29, wherein the B cell is a primary B cell, a plasma cell, a B cell line, naïve B cell, memory B cell, or a plasma blast.

### Claim 31 (depends on 29, 30)

The B cell of any one of claim 29 or 30, wherein the gene of interest is a therapeutic gene or encodes a therapeutic protein.

### Claim 32 (depends on 31)

The B cell of claim 31, wherein the therapeutic gene encodes an enzyme, a cancer antigen, a cytokine, a chemokine, a B cell receptor, a cell surface receptor, or an antibody.

### Claim 33 (depends on 29, 32)

The B cell of any one of claim 29 or 32, wherein the gene of interest is a donor polynucleotide that corrects a mutated genotype in a subject.

### Claim 34 (depends on 28, 29, 30, 31, 32, 33)

A method of treating a disease or condition in a subject in need thereof comprising administering to the subject a gene edited B cell or population of B cells of any one of claims 28-33.

### Claim 35 (depends on 34)

The method of claim 34, wherein the disease is an enzymopathy, a cancer, a precancerous condition, an infection, or a genetic disorder.

### Claim 36 (depends on 34, 35)

The method of claim 34 or 35, wherein the disease is an enzymopathy.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the enzymopathy is selected from the group consisting of aspartylglucosaminuria, cholesterol ester storage disease, Wolman disease, metachromatic leukodystrophy, Danon disease, Fabry disease, Farber lipogranulomatosis, Farber disease, fucosidosis, galactosialidosis types I/II, Gaucher disease types I/II/III, globoid cell leukodystrophy, Krabbe disease, glycogen storage disease II, Pompe disease, GM1-gangliosidosis types I/II/III, GM2-gangliosidosis type I, Tay Sachs disease, GM2-gangliosidosis type II, Sandhoff disease, GM2-gangliosidosis, α-mannosidosis types I/II, β-mannosidosis, mucolipidosis type I, sialidosis types I/II, mucolipidosis types II/III, I-cell disease, mucolipidosis type IIIC, pseudo-Hurler polydystrophy, mucopolysaccharidosis type I, mucopolysaccharidosis type II, Hunter syndrome, mucopolysaccharidosis type IIIA, Sanfilippo syndrome, mucopolysaccharidosis type IIIB, mucopolysaccharidosis type IIIC, mucopolysaccharidosis type IIID, mucopolysaccharidosis type IVA, mucopolysaccharidosis type IVB Morquio syndrome, mucopolysaccharidosis type VI, mucopolysaccharidosis type VII, Sly syndrome, mucopolysaccharidosis type IX, multiple sulfatase deficiency, neuronal ceroid lipofuscinosis, CLN1 Batten disease, CLN2 Batten disease, Niemann-Pick disease types A/B, Niemann-Pick disease, Niemann-Pick disease type C1, Niemann-Pick disease type C2, pycnodysostosis, Schindler disease types I/II, and sialic acid storage disease, hemophilia A, hemophilia B, Christmas disease, and Factor VII deficiency.

### Claim 38 (depends on 37)

The method of claim 37, wherein the enzymopathy is mucopolysaccharidosis type I (MPS I) and the gene of interest is iduronidase.

### Claim 39 (depends on 35)

The method of claim 35, wherein the cancer is a solid tumor or a blood cancer.

### Claim 40 (depends on 35, 39)

The method of claim 35 or 39, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head and neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovarian (germ cell) cancer, pancreatic cancer, penile cancer, prostate cancer, retinoblastoma, skin cancer, soft tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva, and Wilms's tumor.

### Claim 41 (depends on 35)

The method of claim 35, wherein the genetic disorder is selected from the group consisting of muscular dystrophy, cystic fibrosis, Sickle cell anemia, β-thalassemia, a lysosomal storage disorder, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID), Retinitis Pigmentosa, macular degeneration, and Wiskott-Aldrich Syndrome.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 35-41, wherein the B cell is a primary B cell, a plasma cell, a mature B cell, a naïve B cell, a memory B cell, or a plasma blast.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 35-42, wherein the B cell is first isolated from the subject to be treated and then genetically modified according to the method of any one of claims 1-27.
